Home › Funds › Foresite Capital Management VI LLC › JBIO
Foresite Capital Management VI LLC position in JBIO
JADE BIOSCIENCES INC · Health Care
Foresite Capital Management VI LLC reported holding 886,667 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$12.5M, representing 2.20% of its reported portfolio and ranking #15 among its reported holdings. Foresite Capital Management VI LLC has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Foresite Capital Management VI LLC's JBIO position evolved
Foresite Capital Management VI LLC first disclosed a stake in JBIO in Q1 2026 at 320,000 shares (US$4.5M). The position peaked in Q2 2026 at 886,667 shares, worth US$19.7M. Across 3 filings, Foresite Capital Management VI LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 886,667 shares valued at US$12.5M. Notable position changes include a 177% increase in Q2 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 320.00K | $4.50M | New |
| Q2 2026 | 886.67K | $19.70M | Add |
| Q3 2026 | 886.67K | $12.46M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 81 other funds we track also report a position in JBIO — the largest reported positions include Paradigm Biocapital Advisors LP (US$85.0M), Fairmount Funds Management LLC (US$64.0M), Bellevue Group AG (US$60.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Paradigm Biocapital Advisors LP 6.05M sh · $85.05M · Q3 2026
- Fairmount Funds Management LLC 4.55M sh · $63.98M · Q3 2026
- Bellevue Group AG 4.29M sh · $60.33M · Q3 2026
- Venrock Adviser, LLC 3.22M sh · $45.25M · Q3 2026
- Avidity Partners Management LP 2.00M sh · $28.10M · Q3 2026
- RA CAPITAL MANAGEMENT, L.P. 1.84M sh · $25.79M · Q3 2026
- Remedium Capital Partners, LLC 1.81M sh · $25.40M · Q3 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $17.29M · Q3 2026
- Soleus Capital Management, L.P. 1.17M sh · $16.45M · Q3 2026
- Versant Venture Management, LLC 991.78K sh · $13.93M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $13.86M · Q3 2026
- Affinity Asset Advisors, LLC 760.35K sh · $10.68M · Q3 2026
More on Foresite Capital Management VI LLC
FAQ
How long has Foresite Capital Management VI LLC held JBIO?
Foresite Capital Management VI LLC has disclosed JBIO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Foresite Capital Management VI LLC's current position in JBIO?
As of Q3 2026, Foresite Capital Management VI LLC holds 886.67K shares of JBIO (JADE BIOSCIENCES INC), valued at $12.46M, representing 2.20% of its reported portfolio and ranking #15.
Has Foresite Capital Management VI LLC been buying or selling JBIO?
In the latest 13F filing (Q3 2026), Foresite Capital Management VI LLC held unchanged its position in JBIO. The position peaked in Q2 2026 at 886.67K shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Paradigm Biocapital Advisors LP, Fairmount Funds Management LLC, Bellevue Group AG, among 81 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.